Literature DB >> 11015389

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

M A Pfaller1, S A Messer, A Houston, K Mills, A Bolmstrom, R N Jones.   

Abstract

Performance of the Etest for voriconazole susceptibility testing of 312 isolates of Candida spp. was assessed against that of the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degrees C. Etest MICs were determined with RPMI agar containing 2% glucose (RPG), Casitone agar (CAS), and antibiotic medium 3 (AM3) agar and were read after incubation for 48 h at 35 degrees C. The Candida spp. isolates included C. albicans (n = 174), C. glabrata (n = 55), C. tropicalis (n = 31), C. parapsilosis (n = 39), C. krusei (n = 5), C. lusitaniae (n = 2), and C. guilliermondii (n = 6). The Etest results obtained using RPG correlated well with the reference MICs. Overall agreement ranged from 91% for C. glabrata to 100% for C. tropicalis, C. parapsilosis, C. guilliermondii, C. krusei, and C. lusitaniae. When CAS was used, agreement ranged from 80% for C. krusei to 100% for C. parapsilosis, C. guilliermondii, and C. lusitaniae. With AM3, agreement ranged from 58% for C. glabrata to 100% for C. lusitaniae and C. guilliermondii. The Etest method using RPG appears to be a useful method for determining voriconazole susceptibilities of Candida species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015389      PMCID: PMC87462     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds.

Authors:  A Szekely; E M Johnson; D W Warnock
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

2.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing.

Authors:  A L Colombo; F Barchiesi; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

3.  In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.

Authors:  M Ruhnke; A Schmidt-Westhausen; M Trautmann
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

7.  Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.

Authors:  S C Chen; M L O'Donnell; S Gordon; G L Gilbert
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

8.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.

Authors:  A L Colombo; F Barchiesi; D A McGough; A W Fothergill; M G Rinaldi
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

View more
  18 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

5.  Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.

Authors:  Vânia Lúcia Ribeiro da Matta; Márcia de Souza Carvalho Melhem; Arnaldo Lopes Colombo; Maria Luiza Moretti; Laura Rodero; Gisele Madeira Duboc de Almeida; Marilena dos Anjos Martins; Silvia Figueiredo Costa; Maria Beatriz G Souza Dias; Márcio Nucci; Anna S Levin
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

6.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

7.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Authors:  M J Maxwell; S A Messer; R J Hollis; L Boyken; S Tendolkar; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

8.  E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

Authors:  Ana Espinel-Ingroff; A Rezusta
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 9.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.